Media stories about Opexa Therapeutics (NASDAQ:ACER) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Opexa Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.7837631552227 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Opexa Therapeutics (NASDAQ:ACER) opened at $13.50 on Tuesday. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63. The company has a market capitalization of $99.46, a price-to-earnings ratio of -2.35 and a beta of 2.26.

Opexa Therapeutics (NASDAQ:ACER) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter. equities research analysts predict that Opexa Therapeutics will post -1.48 EPS for the current year.

A number of equities research analysts recently weighed in on ACER shares. HC Wainwright started coverage on Opexa Therapeutics in a research note on Wednesday, December 20th. They issued a “buy” rating on the stock. ValuEngine raised Opexa Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd.

ILLEGAL ACTIVITY WARNING: “Opexa Therapeutics (ACER) Earns Coverage Optimism Score of 0.01” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with's FREE daily email newsletter.